Chen Xiaohui, Yu Yilin, Wu Haishan, Qiu Jianjian, Ke Dongmei, Wu Yahua, Lin Mingqiang, Liu Tianxiu, Zheng Qunhao, Zheng Hongying, Yang Jun, Wang Zhiping, Li Hui, Liu Lingyun, Yao Qiwei, Li Jiancheng, Cheng Wenfang
Department of Thoracic Surgery, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, China.
College of Clinical Medicine for Oncology, Fujian Medical University, Fuzhou, China.
Front Oncol. 2022 Jun 1;12:896788. doi: 10.3389/fonc.2022.896788. eCollection 2022.
We aimed to determine whether the tumor length and tumor thickness should be used as prognostic factors for esophageal squamous cell carcinoma (ESCC) patients treated with definitive chemoradiotherapy (dCRT).
A retrospective analysis consists of 902 non-operative ESCC patients received dCRT. The nomogram was used to predict the survival. Besides, Restricted Cubic Splines (RCS) was used to examine the relationship between prognostic factors and survival outcomes. Finally, the prognostic index (PI) scores were constructed according to the tumor length and tumor thickness, and the patients were divided into the low-, medium-, and high-risk groups.
The median follow-up of overall survival (OS) and progression-free survival (PFS) were 23.0 months and 17.5 months. Multivariate Cox regression analysis showed that tumor length and tumor thickness were independent prognostic factors associated with survival. Our novel nomograms for OS and PFS were superior to the TNM classification (p < 0.001). Besides, RCS analysis demonstrated that the death hazard of tumor length and tumor thickness sharply increased at 7.7 cm and 1.6 cm (p < 0.001). Finally, there were significant differences for ESCC patients with clinical TNM stage group of the OS and PFS in different risk groups. The higher risk group was significantly associated with shorter OS and PFS in ESCC patients (both p < 0.001 for all).
The study results suggest that the novel models integrating tumor length and tumor thickness may provide a simple and widely available method for evaluating the prognosis of non-operative ESCC patients. The tumor length and tumor thickness should be considered as prognostic factors for ESCC.
我们旨在确定肿瘤长度和肿瘤厚度是否应作为接受根治性放化疗(dCRT)的食管鳞状细胞癌(ESCC)患者的预后因素。
一项回顾性分析纳入了902例接受dCRT的非手术ESCC患者。使用列线图预测生存情况。此外,采用限制性立方样条(RCS)来检验预后因素与生存结果之间的关系。最后,根据肿瘤长度和肿瘤厚度构建预后指数(PI)评分,并将患者分为低、中、高风险组。
总生存(OS)和无进展生存(PFS)的中位随访时间分别为23.0个月和17.5个月。多因素Cox回归分析显示,肿瘤长度和肿瘤厚度是与生存相关的独立预后因素。我们新构建的OS和PFS列线图优于TNM分期(p < 0.001)。此外,RCS分析表明,肿瘤长度和肿瘤厚度的死亡风险在7.7 cm和1.6 cm时急剧增加(p < 0.001)。最后,不同风险组的ESCC患者在临床TNM分期组的OS和PFS存在显著差异。高风险组与ESCC患者较短的OS和PFS显著相关(所有p均< 0.001)。
研究结果表明,整合肿瘤长度和肿瘤厚度的新模型可能为评估非手术ESCC患者的预后提供一种简单且广泛可用的方法。肿瘤长度和肿瘤厚度应被视为ESCC的预后因素。